Impact of Metformin and Pioglitazone on Serum Level of Tumor Necrosis Factor-Alpha and Lipid Profiles during Implantation Window in Diabetic Rats

Abstract

Background: The present study was designed to evaluate serum lipid profile and tumor necrosis factor-alpha (TNF-alpha) level in diabetic rats at implantation time. Type 2 diabetes mellitus (T2DM) could affect various systems, including innate immune system and it causes chronic low-grade inflanunation, increasing level of TNF-alpha. Furthermore, T2DM is often accompanied by impaired lipid profile. Metformin and pioglitazone are used as the first and second lines of treatment for T2DM. Materials and Methods: In this experimental study, 35 adult virgin female wistar rats, weighting 175-225 g, were randomly categorized into five groups: i. Control, ii. Sham, iii. Nicotinamide (NA)+streptozotocin (STZ) induced T2DM, iv. Diabetic+pioglitazone (20 mg/kg/day for 28 days oral administration), and v. Diabetic+metformin (100 mg/kg/day for 28 days oral administration). At the time of implantation. TNF-alpha level in serum of rats was measured by ELISA kit. Glucose was measured using photometric method and lipid profiles were calculated by enzymatic methods. Results: Level of TNF-alpha in the diabetic group was significantly higher than other groups (P<0.001). In metformin treated group, TNF-alpha serum level was also significantly higher than pioglitazone treated group (P<0.001). Fasting blood sugar (FBS) and lipid profiles were significantly higher in diabetic group. Conclusion: Metformin and pioglitazonc have similar effects on glucose, lipid profiles and TNF-alpha serum levels. Among these drugs, pioglitazone has more efficient influence on TNF-alpha serum level, in comparison with metformin.